Clinical Trial Update: Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Celecoxib in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intraductal Papillary Mucinous Neoplasm
• Pancreatic Neoplasms

Drugs mentioned

• Celecoxib (Celecoxib)

Snippet

Sponsor: Indiana University School of Medicine | Conditions: Pancreas Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2016-02-29